Moderna's mRNA Flu Shot Could Signal a Turnaround for Investors
Moderna (MRNA) may be shifting perceptions as the FDA prepares to evaluate its mRNA-based flu shot, MFLUSIVA. The company is seeking validation that its platform can deliver repeatable revenue beyond pandemic-era success with its original vaccines.
Tickers: $MRNA
Topics: financial performance investor sentiment mRNA technology vaccines